Mesenchymal Stem Cells as a Biological Drug for Heart Disease
Where Are We With Cardiac Cell–Based Therapy?
Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.
- cell- and tissue-based therapy
- clinical trial
- chronic heart failure
- heart disease
- mesenchymal stem cells
- Received February 22, 2015.
- Revision received May 21, 2015.
- Accepted June 15, 2015.
- © 2015 American Heart Association, Inc.